Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 10/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TERT | O14746 | 5/20 | 0.84 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.83 |
| ▸ | CCR6 | P51684 | 1/20 | 0.83 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.83 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.83 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pristimerin SCHEMBL30271494 | 1.00 | NR4A1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| Pristimerin SCHEMBL17328930 | 1.00 | NR4A1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| Pristimerin SCHEMBL31238187 | 1.00 | NR4A1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| SCHEMBL18782114 | 0.91 | NR4A1 (0.84) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| SCHEMBL12395123 | 0.91 | NR4A1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| SCHEMBL12395120 | 0.91 | NR4A1 (0.83) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| Celastrol SCHEMBL17130559 | 0.91 | HSP90AA1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| Celastrol SCHEMBL14954 | 0.91 | HSP90AA1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| Celastrol SCHEMBL17430781 | 0.91 | HSP90AA1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E | |
| Celastrol SCHEMBL15813281 | 0.91 | HSP90AA1 (1.00) | NR4A1PTPN1CASP1ABHD6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1035 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734960-A1 | STEROL ANALOGS IN LIPID NANOPARTICLE FORMULATIONS | Sanofi Pasteur Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4479072-B1 | COMPOSITION COMPRISING A MYRTLE EXTRACT AND A TRIPTERYGIUM WILFORDII EXTRACT FOR CONTROLLING ACNE OF NON-LESIONAL AREAS OF ACNEIC SKIN | PIERRE FABRE DERMO COSMETIQUE (FR) | 2026-03-04 | — | — | EP | claimed |
| US-20260014065-A1 | PHYTOCHEMICAL INFUSED COSMETIC COMPOSITIONS AND THERAPEUTIC USES THEREOF | Dewey Beauty LLC (US) | 2026-01-15 | — | — | US | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4529452-B1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI SPA (IT) | 2025-12-24 | — | — | EP | claimed |
| CN-120189419-A | Application of pristimerin in preparation of medicine for treating colorectal cancer | 上海医药工业研究院有限公司 | 2025-06-24 | — | — | CN | claimed |
| US-12324801-B2 | Water soluble compositions comprising purified cannabinoids | CANOPY GROWTH CORPORATION (CA) | 2025-06-10 | — | — | US | claimed |
| US-20250170038-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | GIULIANI S.P.A. (IT) | 2025-05-29 | — | — | US | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| EP-4529452-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | Giuliani S.p.A. (IT) | 2025-04-02 | — | — | EP | claimed |
| US-20100144685-A1 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2010-06-10 | — | — | US | claimed |
| CN-101519420-A | Method for preparing high-purity pristimerin by high-speed counter-current chromatography | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-09-02 | — | — | CN | claimed |
| WO-2009026163-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | WO | claimed |
| US-20090054438-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009020601-A2 | ATF4 INHIBITORS AND THEIR USE FOR NEURAL PROTECTION, REPAIR, REGENERATION, AND PLASTICITY | CORNELL UNIVERSITY (US) | 2009-02-12 | — | — | WO | claimed |
| WO-2008122038-A1 | REGULATING AUTOPHAGY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-09 | — | — | WO | claimed |
| WO-2008045955-A9 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION (US) | 2008-10-02 | — | — | WO | claimed |
| WO-2008045955-A2 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-04-17 | — | — | WO | claimed |
| CN-1155610-C | Pristimerin series dorivative possessing antioxidation and antitumour activity and its synthesis method | 浙江大学 | 2004-06-30 | — | — | CN | claimed |
| CN-1410434-A | Pristimerin series dorivative possessing antioxidation and antitumour activity and its synthesis method | UNIV ZHEJIANG (CN) | 2003-04-16 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170038-A1 | DOSAGE FORMS FOR TOPICAL ADMINISTRATION OF PENTACYCLIC TRITERPENES | MAS1, CYP51A1, EYA2 | NR4A1 1881/4885PTPN1 2665/4885CASP1 2741/4885 |
| US-20260014065-A1 | PHYTOCHEMICAL INFUSED COSMETIC COMPOSITIONS AND THERAPEUTIC USES THEREOF | DHCR24, CNR2, DSG1 | NR4A1 2531/4885PTPN1 4244/4885CASP1 4114/4885 |
| US-20090054438-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | API5, ACIN1, MCL1 | NR4A1 4146/4885PTPN1 3917/4885CASP1 440/4885 |
| US-12324801-B2 | Water soluble compositions comprising purified cannabinoids | CNR2, CNR1, S100P | NR4A1 4090/4885PTPN1 2173/4885CASP1 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.